Clinical Trial Update: Substance Use Disorder (SUD)-Associated Infections' Treatment With Dalbavancin ENabling OUtpatient Transition [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 trial evaluating dalbavancin for treating SUD-associated infections to enable outpatient transition was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gram-positive Bacteraemia
• Gram-positive Bacterial Infections
• Intravenous Substance Abuse
• Substance Use Disorders

Drugs mentioned

• Dalbavancin (dalbavancin)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Gram-Positive Bacterial Infections, Gram-Positive Bacteraemia | Phase 2, Phase 3 | Status: TERMINATED